

Applicants: Gary A. Beaudry and Paul J. Maddon
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 3

- Sub C1*
- 39. (New) A pharmaceutical composition which comprises the CD4-IgG2 chimeric heterotetramer of claim 36, 37 or 38 in an amount effective to inhibit HIV infection of a CD4+ cell and a pharmaceutically acceptable carrier.--
- Sub B*
- 40. (New) A composition of matter comprising the CD4-IgG2 chimeric heterotetramer of claim 36, 37 or 38 and a toxin linked thereto.--
- Sub C2*
- 41. (New) The composition of claim 40, wherein the toxin is the deglycosylated A chain of ricin, domains II or III of Pseudomonas exotoxin A, or Diphtheria toxin.--
- 42. (New) A diagnostic reagent comprising the CD4-IgG2 chimeric heterotetramer of claim 36, 37 or 38 and a detectable marker linked thereto.--
- 43. (New) The diagnostic reagent of claim 42 wherein the detectable marker is a radioisotope, chromophore or fluorophore.--

REMARKS

Claims 1-29 were originally pending in the subject application. Applicants have hereinabove cancelled claims 1-29, without prejudice to their right to pursue prosecution of these claims in a subsequently filed continuation or divisional application. Applicants have hereinabove added new claims 30-43. Accordingly, claims 30-43 are presently under examination in the subject application.

Applicants: Gary A. Beaudry and Paul J. Maddon
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 4

Applicants maintain that the addition of new claims 30-43 does not raise an issue of new matter. Support for new claims 30-43 may be found in the specification as originally filed, as follows: claim 30, page 19, lines 13-19; claim 31, page 24, lines 30-34; claim 32, page 23, lines 19-21; claim 33, page 23, lines 23-25; claim 34, page 23, lines 31-33; claim 35, page 24, lines 2-4; claim 36, page 27, lines 3-9; claim 37, page 27, lines 11-17; claim 38, page 27, lines 19-21; claim 39, page 29, line 31 through page 30, line 6; claims 40 and 41, page 30, lines 7-19; and claims 42 and 43, page 30, lines 21-31. Applicants therefore respectfully request entry of new claims 30-43.

If a telephone interview would be of assistance in advancing the prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided.

No fee is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any fee is required, authorization is hereby given to charge the amount of such a fee to Deposit Account No. 03-3125.

Respectfully submitted,



John R. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham
30 Rockefeller Plaza
New York, New York 10112
(212) 977-9550